AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Company Growth (employees)
London, GB
Size (employees)
59,700 (est)-2%
AstraZeneca was founded in 1999 and is headquartered in London, GB

Key People at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

Herren Wu

Herren Wu

Mark Mallon

Mark Mallon

Executive Vice President
Menelas Pangalos

Menelas Pangalos

Executive Vice President
Bahija Jallal

Bahija Jallal

Executive Vice President
Jeff Pott

Jeff Pott

General Counsel
Caroline Hempstead

Caroline Hempstead

Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng

Pam Cheng

Executive Vice-President
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Paul Hudson

Paul Hudson

Executive Vice President North America
Fiona Cicconi

Fiona Cicconi

Executive Vice-President, Human Resources

AstraZeneca Office Locations

AstraZeneca has offices in London, Bangalore, Hong Kong, Shanghai and in 170 other locations
London, GB
Schaumburg, US
Pasadena, US
Towson, US
Colorado Springs, US
Eugene, US
Vineland, US
Beverly Hills, US
Silver Spring, US
Bridgewater, US
Manchester, GB
Overland Park, US
Fredericton, CA
Halifax, GB
Hamilton, CA
Livingston, GB
Sarasota, US
Baltimore, US
Gainesville, US
Bethesda, US

AstraZeneca Metrics

AstraZeneca Summary

Market capitalization

$77.9 b

Closing share price

AstraZeneca's current market capitalization is $77.9 b.

AstraZeneca Financials

AstraZeneca's revenue is $23.6 b in FY, 2015 which is a 9.4% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


$25.7 b$26.1 b$23.6 b

Revenue growth, %


Cost of goods sold

$5.3 b$5.8 b$4.6 b

Cost of sales

$3.5 b$4.3 b$3.4 b

Gross profit

$20.5 b$20.7 b$20.1 b

Gross profit Margin, %


Sales and marketing expense

$306 m$324 m$339 m

R&D expense

$4.8 b$5.6 b$6 b

General and administrative expense

$12.2 b$13 b$11.1 b

Operating expense total

$17.3 b$18.9 b$17.4 b

Depreciation and amortization

$4.6 b$3.3 b$2.9 b

Interest expense

($495 m)($963 m)($1.1 b)

Interest income

$50 m$78 m$46 m

Income tax expense

($696 m)($11 m)($243 m)

Net Income

$2.6 b$1.2 b$2.8 b

Operating cash flow

$7.4 b$7.1 b$3.3 b

AstraZeneca Operating Metrics

Y, 2013Y, 2014Y, 2015Y, 2016

Projects in R&D Pipeline


Ongoing Phase III Programs


NME in Late-stage Development


Drugs Approved by FDA


AstraZeneca Market Value History

AstraZeneca Revenue Breakdown

AstraZeneca Online Presence

AstraZeneca News

AstraZeneca Company Life

You may also be interested in